Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Robotic Surgery’s Popularity Pushes Intuitive Surgical Stock Up 65% In Q3

This article was originally published in The Gray Sheet

Executive Summary

Accelerating demand for Intuitive Surgical's da Vinci robotic surgical system procedures is driving the firm's stellar stock price growth, including a 65.7% leap in the third quarter

You may also be interested in...



Hologic Women’s Health Biz Wows Investors As Stock Soars 45% In 2007

Hologic is looking this year to build on its status as the largest company dedicated to women's health care by launching a three-dimensional digital mammography system capable of significantly improved performance over 2D systems

Hologic Women’s Health Biz Wows Investors As Stock Soars 45% In 2007

Hologic is looking this year to build on its status as the largest company dedicated to women's health care by launching a three-dimensional digital mammography system capable of significantly improved performance over 2D systems

Earnings Calls In Brief

Johnson & Johnson/Cordis: Sales of Cypher sirolimus-eluting coronary stents in the United States declined 44% from a year ago to $185 million in the third quarter, the firm reports Oct. 16. Internationally, sales of the device were off 40% to $190 million. The firm blamed reduced percutaneous coronary intervention procedure volumes, a decreased penetration rate for drug-eluting stents versus bare-metal stents, and burgeoning overseas competition. The drug-eluting stent market has declined by over 40% in the United States and over 10% internationally, J&J estimates. The firm believes its share of the U.S. market has been stable at about 46%, while international share of 37% was down from 51% a year ago. Worldwide, Cypher's market share is about 41%, the firm says. Overall, J&J's medical devices and diagnostics segment reported Q3 sales of $5.2 billion, up 6% from a year ago. Company-wide, the diversified drug and medical technology firm generated revenue of $15 billion, up 12.7% from a year ago

Related Content

Topics

UsernamePublicRestriction

Register

MT025371

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel